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Levine and Cagan describe an oncogenic
Ras-driven lung cancer model in
Drosophila that is used in a whole-animal
drug screen of over 1,000 FDA-approved
compounds. Two hits, the MEK inhibitor
trametinib and the statin fluvastatin,
synergized to rescue oncogenic
phenotypes and lethality.
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We have developed a Drosophila lung cancer model
by targeting Ras1G12V—alone or in combination with
PTEN knockdown—to the Drosophila tracheal sys-
tem. This led to overproliferation of tracheal tissue,
formation of tumor-like growths, and animal lethality.
Screening a library of FDA-approved drugs identified
several that improved overall animal survival. We
explored two hits: the MEK inhibitor trametinib and
the HMG-CoA reductase inhibitor fluvastatin. Oral
administration of these drugs inhibited Ras and PI3K
pathway activity, respectively; in addition, fluvastatin
inhibited protein prenylation downstream of HMG-
CoA reductase to promote survival. Combining drugs
led to synergistic suppression of tumor formation
and rescue lethality; similar synergy was observed in
human A549 lung adenocarcinoma cells. Notably,
fluvastatin acted both within transformed cells and
also to reduce whole-body trametinib toxicity in flies.
Our work supports and provides further context for
exploring the potential of combining statins with
MAPK inhibitors such as trametinib to improve overall
therapeutic index.INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality
worldwide, with non-small-cell lung cancer (NSCLC) accounting
for 85% of disease diagnoses. Standard of care commonly in-
cludes a targeted therapy combined with chemoradiotherapy;
multiple targeted therapies are currently approved for use in
NSCLC. These drugs provide important first- and second-line
therapies. In many patients, however, these drugs have shown
limited success in suppressing tumor progression due to limited
efficacy, emergent resistance, and significant toxicity. As a
result, NSCLC continues to represent a significant unmet clinical
need. Current efforts to identify new drugs and drug cocktails
would benefit from whole-animal approaches that account for
complex and often unpredictable drug activities. Here, we pre-
sent a Drosophila model of lung cancer as a platform to identify
and explore candidate therapeutics.Cell RA number of publications have highlighted the similarities be-
tween Drosophila tracheal and vertebrate lung development
(Roeder et al., 2012; Behr, 2010; Andrew and Ewald, 2010).
The Drosophila tracheal system is an extensively branched
tubular network that supplies oxygen to the fly. Both vertebrate
lung and Drosophila tracheal systems are formed from an inter-
connected tubular hierarchy that begins in large primary tubes
and branches into diminishing diameter segments that end in
terminal branches. During Drosophila tracheal development,
the branching process is highly dependent on fibroblast growth
factor (FGF) signaling. Tracheal cells express the FGF receptor
homolog Breathless (Btl), which responds to localized pres-
ence of the FGF ligand Branchless to initiate branching. Verte-
brate lung development relies on FGF signaling in a similar
manner during airway branching (Park et al., 1998; Bellusci
et al., 1997).
Here, we present the results of tracheal-targeted expression of
the oncogenic isoform Ras1G12V plus knockdown of the PI3K-
negative regulator PTEN. Activated Ras isoforms represent the
most-common genetic mutations associated with NSCLC and
are typically associated with activated PI3K pathway signaling
(Kandoth et al., 2013; Cancer Genome Atlas Research Network,
2012). Screening a library of FDA-approved compounds yielded
multiple hits, including the MEK inhibitor trametinib and the
HMG-CoA reductase inhibitor fluvastatin. We provide evidence
that these two drugs act synergistically to reduce the effects of
Ras/PI3K pathway activation. The result is improved tracheal
development, reduced overproliferation, and reduced whole-an-
imal toxicity; the two drugs also acted synergistically to suppress
growth in a standard human lung cancer cell line. We demon-
strate that fluvastatin acts through multiple targets to improve
overall efficacy, and our data suggest that fluvastatin may prove
useful to reduce the whole-body toxicity profiles that are com-
mon to targeted therapies.RESULTS
Drosophila Lung Cancer Model
To reliablymanipulate gene sets,webuilt vectors containingmul-
tiple UAS elements using a ‘‘repeat ligation method’’ (Figure 1A;
see Experimental Procedures). With this reiterative cloning
approach, we created Drosophila lines with transgenes inserted
into the sameattP insertion site to ensure comparable expression
levels. The resulting lines expressed transgenes that directedeports 14, 1477–1487, February 16, 2016 ª2016 The Authors 1477
Figure 1. A Multigenic Drosophila Lung Cancer Model
(A) Multiple UAS-containing transgenes were combined into vectors using a repeat ligation method. Up to four UAS elements were added to a single vector in the
order and orientation shown. The four transgenic lines used in this study are indicated in the lower panel.
(B–C’’) btl > Ras1,PTENi larvae exhibited enlarged and thickened tracheal tubes compared to btl > control larvae. Higher magnification views are shown to
visualize the enlarged nuclei.expression of the oncogenic Ras1 isoform Ras1G12V and/or
RNAi-mediated knockdown of the PI3K pathway inhibitor PTEN
(PTENi), addressing two pathways commonly activated in
NSCLC patients (Kandoth et al., 2013; Cancer Genome Atlas
Research Network, 2012). To express these transgenes within
the Drosophila trachea, we added the driver breathless-gal4
(btl-GAL4) by standard genetic crosses. btl-Gal4 is expressed
primarily in the trachea; expression is also reported in midline
glia within the ventral nerve cord (Shiga et al., 1996). The
result was establishment of four lines: btl > control; btl > Ras1;
btl > PTENi; and btl > Ras1,PTENi. The full genotypes are listed
in Figure 1A; all include expression of the visible marker GFP to
visualize transformed cells.
The transgenic line btl > control directed GFP expression pri-
marily within tracheal tissue throughout development including
the L3 larval stage, confirming specificity of the driver (Fig-
ure 1B). btl > Ras1,PTENi L3 larvae exhibited tracheal tubes
with thicker walls than control animals, likely due to a significant
increase in nuclear size typical of transformed cells (Figures 1C
and S1). In addition, btl > Ras1,PTENi L3 larval tracheal tubes
tended toward increased width (not significant; Figure S1)
and exhibited fine terminal branching (Figure 1C). The result
was a lethal phenotype: at 25C, btl > Ras1 and btl > Ras1,
PTENi survived to pharate (late pupal) stage but exhibited
low levels of eclosion to adulthood. At 29C—a temperature
at which the btl-GAL4 driver is more active—both lines died
during early larval (L1–L2) stages; btl > PTENi—lacking
Ras1G12V—showed no detectable phenotype (data not shown).
Whereas we anticipate that lethality is due to tracheal expres-
sion, we cannot rule out a contribution by btl-GAL4’s midline
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btl > Ras1,PTENi animals die as larvae at 29C. Using a robotics-
based screening approach and a 96-well format (see Experi-
mental Procedures), we screened a library of 1,192 FDA-
approved drugs for those that rescued animals to pupariation
(Figure 2A). Hits were subsequently tested in btl > Ras1 flies.
Drugs were fed orally mixed in the animals’ food, the screen
was performed in duplicate, and potential hits were confirmed
in a larger-scale format.
Eight hits were identified from this screen (Figure 2B). Interest-
ingly, five of the hits are DNA analogs, three of which are used as
chemotherapeutics including capecitabine (5-fluorouracil pro-
drug), decitabine (cytidine analog used to treat acute myeloid
leukemia), and cladribine (purine analog used to treat hairy cell
leukemia). The remaining two DNA analogs were aciclovir and
its prodrug valaciclovir, which are guanosine analog antiviral
drugs. The antioxidant dexrazoxane was also a weak hit. These
provide validation that clinic-relevant hits can be identified in our
screening setup.
Two pathway inhibitor drugs were identified. The targeted
cancer therapeutic trametinib is a highly specific MEK inhibitor
approved for metastatic melanoma. Fluvastatin is an HMG-
CoA reductase inhibitor from the cholesterol-lowering statin
family. Oral administration of trametinib at 1 mM significantly
rescued btl > Ras1 and btl > Ras1,PTENi pupal lethality at
25C (Figures 2C and 2D) and larval lethality at 29C (Figures
2E and 2F). Fifty micromolar fluvastatin directed a mild rescue
of larval lethality in both genotypes (Figures 2E and 2F) but
was ineffective in the more-stringent pupal lethality assay (Fig-
ures 2C and 2D). Along with radiation therapy, targeted therapies
as stand-alone or adjuvant can yield positive outcomes in lungors
Figure 2. A Lethality-Based Large-Scale Drug
Screen
(A) Flowchart of drug experiments. btl > Ras1 com-
binations led to early larval lethality at 29C and late
pupal lethality at 25C; drug efficacy was deter-
mined by measuring the ratio of pupae:embryos at
29C or adults:pupae at 25C.
(B) Nine positive hits from an FDA library screenwere
tested in larger-scale format (*p% 0.05, ** p% 0.01,
*** p% 0.01, and **** p% 0.0001). All drug concen-
trations are mM. Aci, aciclovir; Cap, capecitabine;
Cla, cladribine; Dec, decitabine; Dex, dexrazoxane;
Flu, fluvastatin; Tra, trametinib; Val, valaciclovir.
(C) One micromolar trametinib rescued btl > Ras1
pupal lethality (p% 0.0001) at 25C. Fiftymicromolar
fluvastatin + 0.5 mM trametinib rescued more fully
than 0.5 mM trametinib alone (p% 0.05).
(D) One micromolar trametinib rescued blt >
Ras1,PTEN larval lethality (p % 0.0001) at 25C.
Fluvastatin synergized with trametinib at select
concentrations.
(E) One micromolar trametinib rescued btl >
Ras1,PTENi pupal lethality (p % 0.0001) at 29C;
fluvastatin failed to improve rescue.
(F) Trametinibat0.5mM(p%0.01)and1mM(p%0.05)
rescued btl > Ras1,PTENi larval lethality at 29C; high
levels of fluvastatin failed to improve trametinib-
based rescue in experiments presented in (C)–(F),
presumably due to toxicity at 200 mM.
Values represent mean ± SEM.cancer patients. We therefore focused on the targeted therapeu-
tic drugs trametinib and fluvastatin.
Trametinib and Fluvastatin Synergized to Rescue
Cancer-like Phenotypes
Combining 50 mM fluvastatin with 0.5 mM trametinib signifi-
cantly enhanced rescue of pupal lethality for both genotypes
(Figures 2C and 2D) compared to oral administration of trame-
tinib alone. Further, combining 50 mM fluvastatin with 1 mM tra-
metinib also significantly enhanced rescue of pupal lethality in
btl > Ras1,PTENi (Figure 2D) though not btl > Ras1 (Figure 2C)
compared to 1 mM trametinib alone. Combining fluvastatin with
trametinib did not enhance rescue of larval lethality for either
genotype (Figures 2E and 2F). These data indicate that trame-
tinib is a strong inhibitor of Ras1-based lethality and fluvastatin
is a weaker inhibitor. Combining specific concentrations of
fluvastatin with trametinib yielded synergistic behavior in pro-
moting adult viability that is more robust in btl > Ras1,PTENi
than btl > Ras1 alone. Given the potential clinical relevance ofCell Reports 14, 1477–1487,this two drug combination, we further
explored their ability to synergize.
In the absence of drug, btl > Ras1,PTENi
L3 larvae displayed thickened tracheal
tubes and ectopic fine terminal branching
(Figure 1C). Oral administration of 1 mM tra-
metinib nearly completely suppressed btl >
Ras1,PTENi tracheal phenotypes. Specif-
ically, btl > Ras1,PTENi animals treated
with trametinib did not exhibit the increasedterminal branching phenotype observed inDMSO-fed control an-
imals nor did tracheal cells display the ‘‘bulging’’ nuclei that
contributed to tracheal thickening (Figures 3B, 3C, and S1).
We did not observe overproliferation ormultilayering within the
majority of the btl > Ras1,PTENi tracheal system. The cells that
make up the larval trachea are polyploid (Makino et al., 1938;Ma-
kino, 1938; Edgar and Orr-Weaver, 2001) and are thought to be
terminally differentiated though recent reports suggest they can
divide (Denes et al., 2015; Weaver and Krasnow, 2008). Primary
dorsal branches within the L3 larva’s second tracheal metamere,
however, displayed ectopic cells compared to controls (Fig-
ure S2); this region is populated by dividing imaginal tracheo-
blasts (Guha and Kornberg, 2005). The second tracheal meta-
mere is the source of mitotically active imaginal tracheoblasts
(IT) that are used to repopulate the tracheal system during the
larval-to-pupal transition. The second tracheal metamere is
bound to the larval wing disc via a transverse connective tracheal
branch, which also connects the wing disc to a specialized
tracheal structure called the ‘‘air sac precursor’’ (ASP). The ASPFebruary 16, 2016 ª2016 The Authors 1479
(legend on next page)
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is the larval precursor to the large adult dorsal air sacs and pro-
vides a readily visualized assay. At the L3 stage of larval develop-
ment, the ASP forms from a small population of mitotically active
cells (Sato and Kornberg, 2002), proliferating and migrating to-
ward a localized signal of FGF in the dorsal notum region of the
wing disc (Sato and Kornberg, 2002). During the animal’s transi-
tion from larva to pupa, themajority of larval tracheal cells will his-
tolyze; the pupal trachea is repopulated from imaginal cells
similar to those that form the ASP (Yin and Thummel, 2005).
btl > Ras1,PTENi animals displayed a range of ASP pheno-
types (Figures 3D–3G). Forty-two percent of dissected btl >
Ras1,PTENi wing discs lacked ASPs and 19% were small or
abnormally shaped (Figure 3G), suggesting that these ASPs
failed to form properly. Thirty-nine percent of btl > Ras1,PTENi
ASPs were enlarged; some were significantly overgrown and
filled the dorsal region of the wing disc whereas others displayed
milder overgrowth phenotypes (Figures 3E and 3F). 0.5 mM tra-
metinib reduced the percentage of animals with absent ASPs to
23%compared to 42% in control animals fedDMSO. Fiftymicro-
molar fluvastatin also led to a mild rescue of ASP loss (31%).
Combining trametinib plus fluvastatin decreased the percent-
age of absent ASPs to 17% (Figure 3I) and greatly increased the
percentage of normal ASPs to 32%compared to fluvastatin (6%)
or trametinib (0%) alone (Figure 3I). We observed no strongly
overgrown ASPs in animals fed the two-drug combination (Fig-
ure 3I). Control btl > Ras1,PTENi animals fed DMSO had ASPs
that comprised 15% of total wing disc size (Figure 3J). Fluvasta-
tin and trametinib lowered ASP volumes to 11% and 8%,
respectively. Combining the two drugs further rescued ASP
size to 6%, similar to control levels of 4% (Figure 3J).
The ASPmatures into dorsal air sacs that are visible in late pu-
pae within the dorsal thorax (Figure 3K). Air sacs in the head
formed from dilations of the larval cervical trachea are also
visible (Figure 3K). Most btl > Ras1 and btl > Ras1,PTENi pupae
displayed a loss of these air sacs (Figures 3L and 3M), consistent
with the absence of ASPs observed in larval stages; overall, only
20% retained intact dorsal air sacs. This number was strongly
improved to 75% in trametinib-fed animals (Figures 3O–3Q),Figure 3. Trametinib and Fluvastatin Rescue Tracheal Defects
(A–A’’) btl > control whole larvae (A) and dissected (A’ and A’’) trachea.
(B–B’’) btl > Ras1,PTENi whole larvae have increased fine tracheal branching (B
enlarged cell nuclei (B’ and B’’).
(C–C’’) One micromolar trametinib rescued blt > Ras1,PTENi ectopic fine trache
(D–G) btl > Ras1,PTENi exhibited multiple alterations in anterior sac precursor (A
overproliferation (F), and abnormal shape (G).
(H) Representative btl > Ras1,PTENi ASP rescued by 0.5 mM trametinib + 50 mM
(I) In btl > Ras1,PTENi animals, 0.5 mM trametinib + 50 mM fluvastatin increased
overgrown ASP phenotypes compared to either drug alone.
(J) In btl > Ras1,PTENi animals, ASPs comprised 15% of wing disc volume com
trametinib significantly (p% 0.01) rescued ASP overgrowth. Combining both drug
(K) Pupal air sacs in whole pupae were visible in btl > control animals in the head
(L and M) btl > Ras1 or btl > Ras1,PTENi animals exhibited loss of pupal air sacs
(N–P) Compared to btl > control animals (N), 1 mM trametinib rescued pupal air s
animals.
(Q) Quantification of 1 mM trametinib rescue of btl > Ras1 (p% 0.01) and btl > R
(R–U) Dissected btl > Ras1,PTENi pupae had large GFP-positive abdominal tum
pupal casing (T).
(V) One micromolar trametinib consistently rescued formation of pupal abdomina
All experiments were performed at 25C except ASP phenotyping at 27C. Value
Cell Rconsistent with trametinib’s rescue of larval ASP loss. We also
noted ectopic, GFP-positive tumor-like structures present in
the abdominal regions of btl > Ras1 and btl > Ras1,PTENi pupae
(Figures 3L and 3M). During metamorphosis, most larval tissue
including the tracheal epithelium histolyze and are replaced by
imaginal tissue (Djabrayan et al., 2014; Cabernard and Affolter,
2005; Sato and Kornberg, 2002). These GFP-positive abdominal
tumor-like foci likely derive from regions that failed to histolyze
properly (Figures 3R and 3U); alternatively, they may represent
migrating cells from larval tracheal areas such as the ASP, which
contains cells that endogenously express MMP-1 and migrate
across the wing disc. Trametinib consistently reduced the levels
of btl > Ras1,PTENi GFP-positive abdominal foci (Figure 3V;
n = 60). Fluvastatin alone had no effect, and combining fluvasta-
tin with trametinib did not lead to further reduction (data not
shown), presumably due to the already high level of rescue by
trametinib alone (Figure 3Q).
btl > Ras1,PTENi abdominal ‘‘tumors’’ expressed the cancer
biomarker MMP1 (Figure 3S). MMP1 is often associated with
metastasis (Kessenbrock et al., 2010), and we used time-lapse
movies to determine whether btl > Ras1,PTENi abdominal tu-
mors showed migration. GFP-positive cells were observed to
migrate significant distances in btl > Ras1,PTENi pupae (Movie
S1); similarly, migrating cells were not observed in controls
with the caveat that the tracheal system is dynamically recon-
structing at this stage and control pupae did not display GFP
at strong enough levels to serve as a fully useful comparison.
Fluvastatin Reduced Trametinib’s IC50 in Human Lung
Cancer Cells
To determine whether they exhibited similar synergy in a stan-
dard human lung cancer model, the effects of trametinib and
fluvastatin were examined in A549 cells, a human lung adenocar-
cinoma cell line that contains the activated Ras isoform
KRASG12S. Dose-response curves of trametinib (Figure 4A)
and fluvastatin (Figure 4A) identified each drug’s IC50 as
31.68 nM and 5,358 nM, respectively. Trametinib dose-response
curves were then repeated with fixed doses of 1,000–4,000 nM). Dissected btl > Ras1,PTENi trachea displayed thickened tracheal tubes and
al branches, tracheal thickening, and enlarged cell nuclei.
SP) development including ASP absence (D), strong overproliferation (E), mild
fluvastatin.
percentage of normal ASPs and lowered percentage of absent and strongly
pared to 3% in control ASPs. Fifty micromolar fluvastatin mildly and 0.5 mM
s significantly lowered ASP size compared to trametinib alone (bar; p% 0.05).
(arrowhead) and thorax (arrow).
and gain of abdominal tumors (brackets).
acs and inhibited abdominal tumors in btl > Ras1 (O) and btl > Ras1,PTENi (P)
as1,PTENi (p% 0.001) tumor formation.
ors (R and U) that were MMP1 positive (S). Phosphorylated SRC outlined the
l tumors (n = 60).
s represent mean ± SEM.
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Figure 4. Trametinib and Fluvastatin Synergized to Inhibit Growth in
A549 Lung Adenocarcinoma Cells
(A) Percent viability of A549 cells determined by MTT assay plotted on a log-
arithmic molar dose curve scale. Shown are trametinib and fluvastatin single-
drug dose curves and fluvastatin dose curve with fixed trametinib dosing.
(B) IC50 for fluvastatin, trametinib, and trametinib plus fluvastatin, calculated
with Prism software. The combination index (CI) theorem of Chou-Talalay was
used to determine synergy versus additive effects. One to three micromolar
mM fluvastatin lowered the IC50 of trametinib in a synergistic manner.fluvastatin, below its IC50 of 5,358 nM (Figure 4A). Combining flu-
vastatin with trametinib consistently lowered trametinib’s IC50
(Figure 4B). Using the Chou-Talalay method to calculate combi-
nation index (see Experimental Procedures), we determined
that lower doses of fluvastatin (1,000–3,000 nM) exhibited statis-
tical synergy with trametinib (Figure 4B). With these data vali-
dating the drug combination across platforms, we next explored
their mechanisms of action in a whole-animal setting.
Inhibition of HMG-CoA Reductase and Protein
Prenylation Rescued Ras1-Driven Lethality
Fluvastatin is a member of a large family of ‘‘statin’’ drugs that
inhibit HMG-CoA reductase, an activity that has proven useful
clinically for lowering cholesterol (Figure 5A). Two additional
statins, atorvastatin and simvastatin, rescued larval lethality of
btl > Ras1 at 29C at levels comparable to fluvastatin (Figure 5B).
Most invertebrates including Drosophila do not synthesize1482 Cell Reports 14, 1477–1487, February 16, 2016 ª2016 The Authcholesterol. They rely on dietary sources of cholesterol, indi-
cating that the cholesterol-lowering action of statins is not their
mechanism of action. Another important function of the HMG-
CoA reductase pathway is to synthesize the isoprenoid chains
geranylgeranyl pyrophosphate and farnesyl pyrophosphate (Fig-
ure 5A). These are substrates that are added post-translationally
to a variety of proteins—including small GTPases such as Ras—
in a process known as prenylation. Prenylation facilitates attach-
ment to the cell membrane and activation of proteins including
Ras. We blocked prenylation in btl > Ras1 and btl > Ras1,PTENi
flies with oral administration of a geranylgeranyl transferase in-
hibitor (GGTI) and a farnesyl transferase inhibitor (FTI). The
GGTI significantly rescued larval lethality of both btl > Ras1
and btl > Ras1,PTENi at 29C (Figures 5C and 5D) similar to flu-
vastatin and showed synergywith trametinib (Figures 5E and 5F).
FTI had no effect (Figures 5C and 5D). These results are consis-
tent with results observed when combining trametinib and flu-
vastatin, further supporting the view that fluvastatin rescues
lethality by inhibiting production of isoprenoids such as geranyl-
geranyl downstream of HMGCR.
Both btl > Ras1 and btl > Ras1,PTENi displayed elevated levels
of activated, phosphorylated ERK (pERK) on western blots of
dissected L3 tracheal tissue, highlighting activation of the Ras
signal transduction pathway (Figure 6A). As anticipated, trachea
from animals fed 1 mM trametinib had strongly reduced levels of
pERK, below DMSO controls (Figure 6C). Phosphorylation of
the PI3K pathway effector AKT was strongly elevated in btl >
Ras1,PTENi, confirming the pathway is also activated (Figures
6A and 6B). Whereas trametinib had no effect on pAKT, fluvasta-
tin strongly inhibited pAKT elevation in btl > Ras1,PTENi trachea,
indicating that it acted on PI3K pathway activity (Figures 6B
and 6D); fluvastatin also showed mild rescue of pERK in btl >
Ras1,PTENi, but not btl > Ras1 trachea (Figure 6C).
These data suggest that fluvastatin acts to rescue lethality by
at least two mechanisms. Its ability to act by inhibiting PI3K
signaling is consistent with previous mammalian studies (e.g.,
Chu et al., 2006; Li and De Souza, 2011; Son et al., 2007). The
ability of fluvastatin to also rescue lethality caused by Ras1
alone—which did not show elevated levels of pAKT—indicates
that fluvastatin acts through multiple mechanisms; our inhibitor
studies indicate that this includes fluvastatin’s ability to block
protein prenylation.
Fluvastatin Rescued Drug-Mediated Whole-Animal
Toxicity
Whereas up to 1 mM trametinib rescued our transgenic models,
higher doses led to reduced eclosion (emergence of adults):
2 mM trametinib led to poor survival in both cancer models and
controls that we attributed to whole-animal toxicity. However,
combining 50 mM fluvastatin with 2 mM trametinib still led to
rescue of btl > Ras1,PTENi pupal lethality (Figure 7A). Feeding
2 mM trametinib to non-transgenic (yw) flies led to a reduced
eclosion rate of 23% compared to 86% of control animals fed
DMSO, indicating significant whole-animal toxicity. Combining
100 mM fluvastatin with 2 mM trametinib increased eclosion
rate to 57% (Figure 7A). These data indicate that a key aspect
of fluvastatin’s synergy with trametinib is its ability to reduce
the latter’s whole-body toxicity profile. Surprisingly, fluvastatinors
Figure 5. Protein Prenylation Inhibition Res-
cues Ras1-Driven Lethality
(A) HMG-CoA pathway. HMG-CoA reductase is the
rate-limiting enzyme in cholesterol synthesis and is
inhibited by statins. The pathway also produces
farnesyl-PP and geranylgeranyl-PP, substrates
used for protein prenylation. Geranylgeranyl-trans-
ferase and farnesyl-transferase, two enzymes used
in protein prenylation, are inhibited by GGTI and FTI.
Inhibitors are listed in red.
(B) Two additional statins, atorvastatin (p % 0.05)
and simvastatin (p% 0.05), rescued btl > Ras1 larval
lethality in a manner similar to fluvastatin (p% 0.01).
(C and D) The prenylation inhibitor geranylgeranyl
transferase inhibitor (GGTI) rescued lethality
directed by btl > Ras1 (C; 50 mM, p% 0.05; 100 mM,
p% 0.01) and btl > Ras1,PTENi (D; 50 mM, p% 0.01;
100 mM, p% 0.05).
(E and F) Geranylgeranyl transferase inhibitor (GGTI)
combined with trametinib significantly rescued btl >
Ras1-mediated pupal lethality more strongly than
either drug alone (E; 1 mM trametinib + 100 mMGGTI,
p% 0.05). Though an apparent trend toward synergy
was observed in rescue of btl > Ras1,PTENi lethality,
the results were not statistically significant (F).
Values represent mean ± SEM.was also able to rescue toxic doses of four other drugs: the pro-
teasome inhibitor bortezomib and three mTOR inhibitors (evero-
limus, rapamycin, and temsirolimus; Figure 7A).
To understand how fluvastatin reduced drug toxicity, we
focused on its activity against HMG-CoA reductase. Reducing
enzyme activity by introducing the mutation hmgcrm102023 or
(confirmed hypomorph) hmgcr011522 (Santos and Lehmann,
2004) protected animals from toxicity due to high levels of trame-
tinib or everolimus (Figures 7B and 7C). Exploring further down-
stream (Figure 5A), we reduced activity of Drosophila orthologs
of farnesyl pyrophosphate synthase (FPPS) and geranylgeranyl
diphosphate synthase (GGPS) and examined toxic levels of tra-
metinib or everolimus. The FPPS mutant fppsk03514, previously
demonstrated to decrease levels of Rho prenylation (Cook
et al., 2012), was strongly insensitive to trametinib toxicity and
mildly insensitive to everolimus toxicity (Figures 7B and 7C).
The null allele ggps1qm-L14.4 (Santos and Lehmann, 2004) mildly
rescued everolimus toxicity (not significant) and had no effect on
trametinib toxicity (data not shown). We conclude that, in addi-
tion to its anti-tumor effects, fluvastatin can act to reduce
whole-body toxicity of specific targeted therapeutics to improve
overall therapeutic outcome.
DISCUSSION
A Whole-Animal Drug Screen
Wehave designed aDrosophila transgenicmodel that provides a
whole-animal genetic platform for exploring lung cancer. Pairing
targeted activation of Ras1 with loss of PTEN activity (btl >
Ras1,PTENi) led to a variety of tracheal defects. Lethality was
then used as a quantitative readout to screen a library of 1,192Cell RFDA-approved drugs for the ability to improve overall animal
survival. Several hits were known anti-cancer drugs including
DNA analogs that presumably act to decrease overproliferation,
validating our approach. Our screen also identified a synergistic
relationship between the MEK inhibitor trametinib and the HMG-
CoA reductase inhibitor fluvastatin.
OurDrosophilamodel is not a precise mimic of lung adenocar-
cinoma, but it contains important similarities that indicate it can
be a useful one. Pairing oncogenic Ras1 with a knockdown of
PTEN within the trachea resulted in overproliferation of larval tis-
sue, loss of pupal air sacs, and generation of tumor-like growths
in the pupal abdomen. All phenotypes were strongly rescued
by trametinib and by trametinib/fluvastatin combinations. Low-
dose fluvastatin significantly lowered the IC50 of trametinib in
inhibiting growth of the Ras1G12V-positive A549 lung adenocarci-
noma cell line, demonstrating that fluvastatin acts in part by opti-
mizing trametinib activity within transformed cells. Importantly,
the whole-animal aspect of the models also allowed us to distin-
guish between drug combinations that are therapeutic to the an-
imal as opposed to solely killing cancer cells. This advantage
was exploited to determine that—in addition to reducing effects
of Ras/PTEN on tracheal integrity—fluvastatin rescued whole-
animal toxicity associated with trametinib independent of its
effects on transformed cells.
Trametinib/Fluvastatin Synergy
Our results show that, as anticipated, the MEK inhibitor tra-
metinib blocked the rise in pERK associated with overexpres-
sion of oncogenic Ras. This is consistent with recent work
demonstrating that trametinib acts in Drosophila to reduce
Ras pathway activity (Slack et al., 2015). Also consistent witheports 14, 1477–1487, February 16, 2016 ª2016 The Authors 1483
Figure 7. Fluvastatin Rescues Toxicity Caused by Other Drugs
(A) Two micromolar trametinib was toxic to control flies; toxicity was rescued
by 50 mMfluvastatin (Flu; p% 0.05). The proteasome inhibitor bortezomib (bor;
p% 0.05) and three mTOR inhibitors—everolimus (eve; p% 0.01), rapamycin
(rap; p % 0.05), and temsirolimus (tem; p % 0.05)—were also toxic at the
specified doses (mM). All were partially rescued by 50 mM fluvastatin.
(B and C)Mutant lines of theDrosophila homologs of HMG-CoA reductase and
farnesyl pyrophosphate synthase were insensitive to trametinib and/or ever-
olimus toxicity.
*p % 0.05, **p % 0.01, ***p % 0.01, and ****p % 0.0001; values represent
mean ± SEM.
Figure 6. Trametinib Reduced pERK, and Fluvastatin Reduced pAKT
Western blots performed on third instar larval tracheal tissue from btl > Ras1 or
btl > Ras1,PTENi.
(A) One micromolar trametinib blocked Ras1-dependent, elevated levels of
phosphorylated ERK (pERK) but had no effect on phosphorylated AKT (pAKT).
(B) One hundred micromolar fluvastatin reduced a PTEN1-dependent eleva-
tion in pAKT.
(C) Quantification of drug effects on pERK levels, which were strongly reduced
by trametinib (Ras1, p% 0.05; Ras1,PTENi, p = 0.2513) andweakly reduced by
fluvastatin (Ras1,PTENi, p = 0.5564).
(D) Trametinib had no effect on pAKT. Fluvastatin reduced pAKT in btl >
Ras1,PTENi larvae (p% 0.05). Values represent mean ± SEM.mammalian in vitro and in vivo data (Park et al., 2013; Mo-
hammed et al., 2012; Miraglia et al., 2012; Mistafa and Stenius,
2009), statins reduced PI3K pathway activity in Drosophila as
assessed by reduced phosphorylation of AKT. Though the
mechanism underlying statins’ role in inhibiting PI3K signaling
is not well understood, they may disrupt protein-protein inter-
actions such as KRAS/PI3K (Chen et al., 2013). Fifty micromolar
fluvastatin combined with 1 mM trametinib had a significant
effect on btl > Ras1,PTENi lethality compared to no change in
btl > Ras1 alone (Figures 2C and 2D). This is consistent with flu-
vastatin’s effects on Pi3K signaling. Fluvastatin was not able to
consistently enhance trametinib’s ability to rescue lethality
across all drug concentrations, genotypes, and temperatures.
For example, fluvastatin failed to enhance trametinib-based
rescue of larval lethality at 29C (Figures 2E and 2F), possibly
reflecting the additional time available to act or differences in
larval versus pupal structures.
Statins are traditionally used as cholesterol-lowering drugs.
However, Drosophila do not synthesize their own cholesterol
(Santos and Lehmann, 2004), indicating that this is not themech-
anism by which fluvastatin is acting to reduce Ras and PI3K
pathway activity. Rather, our data are consistent with the view
that the anti-cancer activity of statins is due to their ability to
inhibit the synthesis of the downstream isoprenoids farnesyl py-
rophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).
Protein prenylation creates a lipidated hydrophobic domain1484 Cell Reports 14, 1477–1487, February 16, 2016 ª2016 The Auththat mediates membrane attachment and protein:protein inter-
actions. Prenylation by FPP andGGPP are critical for post-trans-
lational modification of Ras and RhoA proteins, respectively (Mo
and Elson, 2004), and inhibiting geranylgeranyl transferase
rescued lethality in our Drosophila lung cancer models. In
mammalian systems, inhibition of Rho protein geranylgeranyla-
tion (rather than farnesylation of Ras) is likely an important aspect
of the anti-cancer effects of statins (Mo and Elson, 2004; Kon-
stantinopoulos et al., 2007; Wong et al., 2002), consistent with
our Drosophila data.
Fluvastatin Reduced Whole-Animal Toxicity
A key discovery of this work is the ability of fluvastatin to reduce
whole-animal toxicity of multiple targeted drugs independent of
its anti-cancer activity. Trametinib is a relatively potent drug
including in our cancer models, rescuing lethality at 1 mM food
concentration; most effective targeted therapies were optimal
within the 100–200 mM range (data not shown). However, trame-
tinib’s efficacywas limited by a narrow therapeutic window: 2 mM
was toxic to both our cancer model and also wild-type animals.ors
This is consistent with a well-described toxic profile of trameti-
nib, which includes rashing, gastrointestinal problems, anemia,
lymphedema, hypertension, and vascular hemorrhaging, and
its use for NSCLC has been limited due to toxicity (Stinchcombe
and Johnson, 2014).
Here, we demonstrate that trametinib’s toxicity was reduced
by fluvastatin. The detailed mechanism behind fluvastatin’s abil-
ity to rescue trametinib toxicity is not entirely clear. One clue
comes from our observation that other targeted therapeutics
were similarly rescued by fluvastatin. Fluvastatin rescued the
toxicity of the mTOR inhibitors rapamycin, temsirolimus, and
everolimus. Inhibition ofmTORC1 relieves proteasomal degrada-
tion of IRS-1 that results in increased PI3K signaling (Carracedo
et al., 2008; O’Reilly et al., 2006; Sun et al., 2005). This suggests
that fluvastatin rescues toxicity associated with mTOR inhibition
by blocking feedback from activated PI3K signaling, perhaps
‘‘re-balancing’’ Ras/PI3K signaling through the body.
Fluvastatin also rescued the toxicity of theproteasome inhibitor
bortezomib. Recent work in our lab suggests that bortezomib can
alter PI3Kpathway signaling (E. Bangi, personal communication).
Other studies have shown that MEK inhibition leads to increased
AKT activation by a negative MEK-EGFR-PI3K feedback loop
(Faber et al., 2009; Yoon et al., 2009; Hoeflich et al., 2009; Mir-
zoeva et al., 2009), again consistent with the view that balanced
Ras/PI3K signaling is required for whole-body homeostasis. The
broad inhibitory nature of statins, due to protein prenylation inhi-
bition, may explain why fluvastatin works well in combination
with MEK and PI3K inhibition both directly on cancer cells and
in rescuing systemic toxicity. Further studies will be required to
determine whether statins show a similar role in improving the
therapeutic indices of targeted therapies in patients.
EXPERIMENTAL PROCEDURES
Drosophila Genotypes Used
The following lines were used: y;w1118, btl-Gal4 (DGRC -109128); hmgcr01152
(BL-11522); hmgcrM102023 (BL-34720); fppsK03514 (BL-10532); and ggppsqm-L14.4
(BL-5828).
In Vitro Assembly of Multi-UAS Vectors
Drosophila genomic DNA from transgenic flies was used to isolate UAS-GFP,
UAS-Dicer1, and UAS-Ras1G12V. A vector from the Vienna Drosophila
Resource Center (VDRC) was used to isolate UAS-PTEN-RNAi (VDRC-
35731). The following oligos were used to add SpeI and AvrII sites to the 50
and 30 ends, respectively:
50-cgcactagttccgtggggtttgaattaac-30
50-cgccctaggacggcgatatttctgtggac-30
AvrII was added to the multicloning region of attB-P[acman]-CmR (DGRC-
1244). AvrII/SpeI-digested PCR-amplified UAS elements were then ligated
into the Pacman vector’s AvrII site in the following order: UAS-GFP; UAS-
Dicer1; UAS-dRasG12V ; and UAS-PTEN-RNAi in four rounds of cloning. Three
vectors (control, Ras1, and Ras1,PTENi) were used to create transgenic lines
at the attP 3L-6435776 location (Bloomington no. 24871).
Drug Studies
The Selleck FDA-approved library (catalog no. L1300) was dissolved in DMSO
buffer to a 100 mM concentration. A PerkinElmer JANUS automated liquid
handler was used to create 1.2 ml 96-well plates (Abgene catalog no. Ab-
1068) containing 300 ml fly food and 0.3 ml drug per well. Drug was added to
molten (50C)-enriched fly food and then left to solidify at room temperatureCell Rto yield 96-well plates of food with 100 mM drug and a DMSO concentration of
0.1%. btl > Ras1,PTENi embryos were suspended in a solution of 10% glyc-
erol, 1% BSA, and 0.1% Tween-20. Five to ten microliters of this slurry was
added to each well at a concentration of 20 embryos. Ninety-six-well plates
covered with a breathable membrane (Sigma catalog no. Z763624) were
placed at 29C and were scored for the presence of pupae. Positive hits
were examined by allowing flies of the indicated genotype to lay 30–60 em-
bryos in 123 75 mm, 5 ml test tubes (Sarstedt catalog no. B00471) containing
1 ml of food/drug at the indicated temperature. All inhibitors were from Selleck
except the farnesyltransferase inhibitor (Enzo catalog no. G242) and geranyl-
geranyltransferase inhibitor (Sigma catalog no. G5169).
Histology
For larval trachea and ASP analysis, third-instar trachea or wing discs were
fixed in 4% paraformaldehyde. For whole-larvae air sac analysis, late stage
pupae (48 hr after pupae formation [APF]) were collected and the pupal cas-
ing was removed prior to imaging. For dissected pupal immunohistochemistry,
pupae (48 hr APF) were frozen in dry ice and then bisected along the anterior-
posterior axis, fixed in 4% paraformaldehyde, blocked in 5% BSA PBS-Triton
0.3%. Antibodies used were directed against MMP1 (Developmental Studies
Hybridoma Bank catalog no. 3B8D12) and phosphorylated SRC (Invitrogen
catalog no. 44660G). Alexa Fluor secondary antibodies were used. Confocal
imaging used a Leica DM5500 Q microscope, and image analysis was per-
formed using Adobe Photoshop. ASP and wing disc size were measured by
pixel counts using Photoshop histogram.
Western Blots
Trachea from 60 third-instar larvae were dissolved in lysis buffer (50 mM Tris,
150 mM NaCl, 1% Triton X-100, and 1 mM EDTA) supplemented with prote-
ase-inhibitor cocktail and phosphatase-inhibitor cocktail (Sigma). Total protein
was quantified using Bio-Rad protein assay. Samples were boiled, resolved on
SDS-PAGE, and transferred by standard protocols. Antibodies used were
from Cell Signaling Technology except ERK (a gift from L. Zipursky) and syn-
taxin (DSHB). ImageJ software was used for quantification.
MTT Assays using A549 Cancer Line
A549 cell line was cultured in DMEMbuffer supplemented with 10%BSA and a
penicillin and streptomycin antibiotics mix. Cells were grown in 75 cm2 sterile
polystyrene culture flasks to 80% confluency, trypsinized, and re-seeded in
equal aliquots into 96-well plates. After 2 days and 50 confluency, media
was removed and replaced with DMSO or drug-containing media. Cells
were allowed to grow for another 6 days, after which the thiazolyl blue tetrazo-
lium bromide (MTT) assay was performed. Cell media was removed and re-
placed with MTT-containing media (1 mg ml1 final concentration), and cells
were allowed to grow at 37C for another 3.5 hr. MTT media was removed
andMTT precipitate dissolved in 4mMHCl, 0.1%NP40 in isopropanol, solvent
by shaking for 1 hr. Spectrophotometric readings at 590 nm and 630 nm using
a 96-well plate reader were used to establish growth and viability of cells. Each
drug dosewas tested in quadruplicates and experiments repeated in triplicate.
Combination index (CI) was determined using the formula outlined by the
theorem of Chou-Talalay: CI = ([Tra]c/[Tra]) + ([Flu]c/[Flu]) + ([Tra]c 3 [Flu]c/
[Tra] 3 [Flu]).
[Tra] and [Flu] are IC50 values of the drugs alone; [Tra]c and [Flu]c are IC50
values of the drugs in combination. CI values were used to determine synergy
(CI < 0.9), additivity (0.9 < CI < 1.1), and antagonism (CI > 1.1) of the drug com-
binations tested (Chou and Talalay, 1983; Chou, 2010).
Time-Lapse Pupal Movies
Late-stage (>48 hr APF) pupae were selected, placed on a microscope slide,
and imaged with a Leica DM5500 Q microscope. Sixty-millisecond exposures
were taken every 7 min. Movie shown is 60 frames (7 hr).
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